Indicated for: autoimmune inflammatory diseases
Substance: tocilizumab (monoclonal antibody)
ATC: L04AC07 (Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors)
Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, used in the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome. By blocking the IL-6 receptor, tocilizumab reduces inflammation and abnormal immune responses.
Tocilizumab is administered either intravenously or subcutaneously, depending on the specific indication and patient preference. The dose and frequency of administration are adjusted based on body weight and disease severity.
Common side effects include upper respiratory tract infections, high blood pressure, headache, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as serious infections or gastrointestinal perforations may occur. Regular monitoring of clinical parameters is essential during treatment.
Tocilizumab is an important therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.